Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

News Conference News HRS 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

July 29, 2021

Risk Stratification Before Noncardiac Surgery Won’t Catch All Myocardial Injury

News Daily News

Risk Stratification Before Noncardiac Surgery Won’t Catch All Myocardial Injury

Yael L. Maxwell

June 28, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

News Daily News

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Yael L. Maxwell

April 09, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

Antithrombotics for Elderly CAD Patients: One Size Doesn’t Fit All

News Daily News

Antithrombotics for Elderly CAD Patients: One Size Doesn’t Fit All

April 05, 2021

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

March 17, 2021

TCTMD’s Top 10 Most Popular Stories for February 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2021

March 02, 2021

Statins in COVID-19: More Signs of Potential Benefit

News Daily News

Statins in COVID-19: More Signs of Potential Benefit

February 26, 2021

Site Investigators Missed Clinical Events in GLOBAL LEADERS

News Daily News

Site Investigators Missed Clinical Events in GLOBAL LEADERS

Michael O'Riordan

February 12, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.